Dr. Anjali Vaidya Provides Perspective to MedPage Today on Findings Related to Adding Sotatercept to Treatment Regimen for Pulmonary Arterial Hypertension in High-Risk Patients

Anjali Vaidya, MD, FACC, FASE, FACP, Co-Director of the Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital, provided perspective to MedPage Today on findings related to adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients, which helped delay serious outcomes in the ZENITH trial. The findings were presented at the American College of Cardiology annual meeting and published in the New England Journal of Medicine.